540 related articles for article (PubMed ID: 31522263)
1. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors.
Wojcik C; Warden BA
Curr Cardiol Rep; 2019 Sep; 21(10):130. PubMed ID: 31522263
[TBL] [Abstract][Full Text] [Related]
2. Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C; Mudaliar S
Diabetes Obes Metab; 2019 Aug; 21(8):1780-1789. PubMed ID: 30957945
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose cotransporter 2 inhibitors and cardiovascular clinical outcomes in acute heart failure: A narrative review.
Rodriguez R; Kaluzna SD
Am J Health Syst Pharm; 2023 Jun; 80(13):818-826. PubMed ID: 36971375
[TBL] [Abstract][Full Text] [Related]
6. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations.
Usman MS; Siddiqi TJ; Anker SD; Bakris GL; Bhatt DL; Filippatos G; Fonarow GC; Greene SJ; Januzzi JL; Khan MS; Kosiborod MN; McGuire DK; Piña IL; Rosenstock J; Vaduganathan M; Verma S; Zieroth S; Butler J
J Am Coll Cardiol; 2023 Jun; 81(25):2377-2387. PubMed ID: 37344038
[TBL] [Abstract][Full Text] [Related]
7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
9. Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs.
Hussain A; Ramsey D; Lee M; Mahtta D; Khan MS; Nambi V; Ballantyne CM; Petersen LA; Walker AD; Kayani WT; Butler J; Slipczuk L; Rogers JG; Bozkurt B; Navaneethan SD; Virani SS
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):933-942. PubMed ID: 37204363
[TBL] [Abstract][Full Text] [Related]
10. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
11. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
[TBL] [Abstract][Full Text] [Related]
12. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.
Margonato D; Galati G; Mazzetti S; Cannistraci R; Perseghin G; Margonato A; Mortara A
Heart Fail Rev; 2021 Mar; 26(2):337-345. PubMed ID: 32901315
[TBL] [Abstract][Full Text] [Related]
13. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
[TBL] [Abstract][Full Text] [Related]
14. Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis.
Chang R; Liu SY; Zhao LM
Medicine (Baltimore); 2021 Nov; 100(47):e27802. PubMed ID: 34964748
[TBL] [Abstract][Full Text] [Related]
15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose Cotransporter-2 Inhibitors in Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus: A Meta-analysis.
Kovil R; Chawla M; Shah T; Sahoo A; Makkar B; Kesavadev J; Seshadri K; Tiwaskar M; Rajput R; Phatak S; Majumdar S; Gupta S
J Assoc Physicians India; 2022 Aug; 70(8):11-12. PubMed ID: 36082726
[TBL] [Abstract][Full Text] [Related]
17. Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 May; 17(1):74. PubMed ID: 29801492
[TBL] [Abstract][Full Text] [Related]
18. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
Imran H; Nester W; Elgendy IY; Saad M
Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
[TBL] [Abstract][Full Text] [Related]
20. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R
Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
